Literature DB >> 12232455

Harm reduction--a treatment approach for resistant smokers with tobacco-related symptoms.

Carlos Jiménez-Ruiz1, Segismundo Solano, Soledad Alonso Viteri, Miguel Barrueco Ferrero, Miguel Torrecilla, Miguel Hernández Mezquita.   

Abstract

Smokers with chronic obstructive pulmonary disease (COPD) appear to represent a hard-core group, and this presents a dilemma for chest physicians. A reduction in cigarette smoking benefits health, and nicotine replacement therapy (NRT) can aid smoking reduction. Hence we studied the efficacy of nicotine gum in helping hard-core smokers with severe COPD to quit. Seventeen smokers with severe COPD (FEV(1) 38-47% of predicted normal) who smoked >30 cigarettes/day but were unable to quit were encouraged to reduce their smoking as much as possible by using 4-mg nicotine gum. Five gradually reduced their daily tobacco consumption and, 18 months after starting NRT, were smoking an average of 6 cigarettes/day while still using nicotine gum. Compared to baseline, their respiratory symptoms had improved, and both FEV(1) and FVC had increased. There was no improvement in pulmonary function in the group of smokers who did not reduce their cigarette consumption. No adverse events relating to nicotine occurred among the patients who used NRT to reduce their smoking. We propose that this reduction approach should be considered for patients with respiratory disease who are unable or unwilling to stop smoking. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12232455     DOI: 10.1159/000064015

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  5 in total

Review 1.  The feasibility of smoking reduction: an update.

Authors:  John R Hughes; Matthew J Carpenter
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

2.  Treatment non-response: Associations with smoking expectancies among treatment-seeking smokers.

Authors:  Lorra Garey; Samar A Taha; Brooke Y Kauffman; Kara F Manning; Clayton Neighbors; Norman B Schmidt; Michael J Zvolensky
Journal:  Addict Behav       Date:  2017-05-09       Impact factor: 3.913

3.  The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

Authors:  Teresa R Franklin; Derek Harper; Kyle Kampman; Susan Kildea-McCrea; Will Jens; Kevin G Lynch; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2009-04-23       Impact factor: 4.492

Review 4.  Interventions to reduce harm from continued tobacco use.

Authors:  Nicola Lindson-Hawley; Jamie Hartmann-Boyce; Thomas R Fanshawe; Rachna Begh; Amanda Farley; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2016-10-13

5.  Exploratory survey study of long-term users of nicotine replacement therapy in Danish consumers.

Authors:  Gitte Borup; Kim Lyngby Mikkelsen; Philip Tønnesen; Lona Louring Christrup
Journal:  Harm Reduct J       Date:  2015-01-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.